|Dr. James B. Breitmeyer||Pres, CEO & Director||N/A||N/A||1954|
|Mr. Richard G. Vincent||Chief Financial Officer||N/A||N/A||1964|
|Ms. Lauren G. Otsuki||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Brian Lannutti Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Hazel M. Aker||Gen. Counsel||N/A||N/A||1956|
Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer. It is also developing a chimeric antigen receptor-T product candidate that targets ROR1, which is currently in preclinical development for treating hematologic cancers and solid tumors. The company is headquartered in San Diego, California.
Oncternal Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.